Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — UBS Conference (May 2013)

44 slides from Auxilium Pharmaceuticals's conference presentation, May 21, 2013

  1. Slide 1: Innovations for Life - UBS Conference

    Innovations for Life® UBS Conference May 21, 2013

  2. Slide 2: Forward-looking statements

    We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: our continued profitability for the year; the Company’s expected f

  3. Slide 3: Overview of 1Q13 and Recent Events

    Overview of 1Q13 and Recent Events Financial / Commercial Total net revenues of $66.2 MM (-10% vs. 1Q12 ) Global Testim® revenue of $45.5 MM (-22% vs. 1Q12) Global XIAFLEX® revenue of $20.7 MM; U.S. XIAFLEX revenue of $12.0MM (-5% vs. 1Q12) Non-GAAP net loss of $2.3 MM vs. non-GAAP net income of $1.

  4. Slide 4: Testim – 1Q13 Commercial Performance

    Testim – 1Q13 Commercial Performance TRT Gel Market Dynamics 1Q13 Prescriptions: +11% vs. 1Q12 4Q12 Prescriptions: +27% vs. 4Q11 Testim Performance 1Q13 U.S. net revenue of $45.3MM; -22% vs. 1Q12 ~$3-4 MM destocking of Testim inventories may have occurred Testim Commercial Dynamics Testim market sha

  5. Slide 5: XIAFLEX – 1Q13 Commercial Performance

    XIAFLEX – 1Q13 Commercial Performance XIAFLEX Performance 1Q13 XIAFLEX U.S. net revenues were $12.0MM; -5% vs. 1Q12 1Q13 XIAFLEX ex-U.S. net revenues were $8.8 MM XIAFLEX Commercial Dynamics Increase of 6.5% in vials shipped to physicians in 1Q13 vs. 1Q12 Market share appears to be trending lower in

  6. Slide 6: 1Q13 Non-GAAP Financial Results

    1 See Appendix for reconciliation of the pro forma non-GAAP financial measures to the closest GAAP financial measures 2 Weighted average common shares were 49.2mm in 1Q2013 and 48.3mm in 1Q2012 3 Pre Actient transaction, which closed on April 26, 2013 Total revenues $73.6 $66.2 -10% Cost of goods so

  7. Slide 7: Actient Transaction is Consistent with Core Strategic Objectives

    Actient Transaction is Consistent with Core Strategic Objectives

  8. Slide 8: Key Transaction Terms

    Key Transaction Terms $585MM in upfront cash and certain contingent consideration Contingency payments of up to $50MM dependent upon achieving certain sales milestones based on future Actient urology sales Warrants to purchase 1.25 MM shares of Auxilium common stock at an exercise price of $17.80/sh

  9. Slide 9: Compelling Strategic Rationale

    Compelling Strategic Rationale Creates a Leading Urology Franchise Diversifies and Balances Product Portfolio Enhances Existing Commercial Efforts Through Combined Sales Force Strong Growth Profile with Expanding Margins Financially Compelling + The “New”

  10. Slide 10: Actient: A Leader in Urology

    Urology Respiratory Product Name: Indication: COPD & Asthma Seasonal allergic rhinitis Description Methylxanthine Antihistamine / Decongestant 2012 Revenue ($MM) Erectile dysfunction Leading Non-Oral Prostacyclin Product 25 Erectile dysfunction Vacuum System 13 Testosterone deficiency Buccal Adhesiv

  11. Slide 11: Actient Audited Revenue By Product

    Actient Audited Revenue By Product 10 17 59 115 $ Millions (1) (1) Source: Actient audited financial statements and supporting ledgers. See slide 31 in the Appendix to this presentation for a detailed explanation of, and cautionary statements regarding, the source of the Actient historical financial

  12. Slide 12: TESTOPEL Enhances TRT Franchise

    TESTOPEL® Enhances TRT Franchise Only FDA approved long-acting implantable testosterone replacement therapy Implanted subcutaneously in doctor’s office and procedure takes ~15 minutes Only form of TRT in U.S. that can restore testosterone for 3-6 months per treatment No boxed warning for secondary e

  13. Slide 13: Poised for Strong Growth

    Poised for Strong Growth Revenues ($MM) Anticipated strong top-line growth over next several years Pro forma 2012 revenue represents 62% growth over 2011 standalone revenues (vs. 15% growth on a standalone basis) (1) Significant operating margin expansion potentially driven by increased sales force

  14. Slide 14: Financially Compelling Transaction

    Financially Compelling Transaction Synergize combined company should be able to generate strong operating cash flow Generates anticipated tax benefit (~$60 MM NPV) which further contributes to improved cash flow (and effectively offsets portion of purchase price) Accelerated use of Auxilium NOLs and

  15. Slide 15: 2013 Guidance

    Total Revenues $325 - 355 $360 – 415 (1) Global Testim Revenues $250 - 265 $210 – 240 XIAFLEX: U.S. Revenues $65 - 75 $55 – 65 Ex-U.S. / Def. Rev $10 - 15 $10 – 15 Total XIAFLEX Revenues $75 - 90 $65 - 80 Total Actient Revenues $85 – 95 (1) R & D Expense (non-GAAP) $45 - 55 S G & A Expense (non-GAAP

  16. Slide 16: Expected Revenue Growth

    Expected Revenue Growth 16 2 Mid-point of guidance; Actient 8 months revenues included 1 See Appendix for reconciliation of the pro forma non-GAAP financial measures to the closest GAAP financial measures 15% 27%

  17. Slide 17: The New Auxilium Portfolio

    Therapeutic Area Nonclinical Phase I Phase II Phase III Approved Urology Male Hypogonadism Testim 1% Male Hypogonadism TESTOPEL Erectile Dysfunction Edex Erectile Dysfunction Osbon ErecAid Male Hypogonadism Striant Peyronie’s Disease CCH Male Hypogonadism T-gel Orthopedics Dupuytren’s Contracture XI

  18. Slide 18: Peyronie's Disease - A Devastating Disorder

    Disease Background Potential symptoms1: penile curvature deformity /deviation, pain with erection, penile shortening, indentations, erectile dysfunction, difficulty with sexual intercourse, loss of self-esteem and depression In literature estimated prevalence for adult men of approx. 5%, but believe

  19. Slide 19: XIAFLEX IMPRESS Study - Summary

    XIAFLEX IMPRESS Study - Summary XIAFLEX showed statistically significant improvements in both co-primary endpoints of the IMPRESS I and II Phase III studies Improvement (p-values of 0.0005 and 0.0059) in penile curvature deformity (physical) Improvement (p-values of 0.0451 and 0.0496) in Peyronie’s

  20. Slide 20: XIAFLEX 3-D Photographic Evaluation

    XIAFLEX 3-D Photographic Evaluation Subject 1106-7852 –Baseline curvature deformity - 45° End of study curvature deformity - 28°(38% Improvement) AUX-CC-802 Photo Sub-Study Subject 38% Improvement

  21. Slide 21: Peyronie's Disease Market Opportunity

    Peyronie’s Disease Market Opportunity Category Invasive Surgical1 Invasive Non-Surgical1 Non-Invasive No Treatment2,4 Description / Examples Plication, grafting, prosthesis Verapamil injection Vitamin E, potaba, colchicine Patient Counts 1,500 – 2,000 3,500 – 4,500 40,000 – 66,500 20,000 – 47,000 Ur

  22. Slide 22: Peyronie's - Key Potential Success Factors

    Peyronie’s- Key Potential Success Factors Define XIAFLEX as Solution to Unmet Medical Need for Serious Condition Optimize Coverage and Mitigate Access Issues Thorough Injection Procedure Training Focused Targeting Activate Product Champions

  23. Slide 23: Cellulite Phase Ib Data Supports Progression into Phase II

    CCH Top-line Day 30 Cellulite Phase Ib Data Supports Progression into Phase II XIAFLEX was well-tolerated in the Cellulite Phase Ib

  24. Slide 24: Frozen Shoulder – Statistically Significant CCH Dose Response in Phase IIa Study

    Frozen Shoulder – Statistically Significant CCH Dose Response in Phase IIa Study Both the 0.58 mg(1mL) and 0.58 mg(2mL) cohort demonstrated statistically significant improvement in pain and function over baseline scores vs. the exercise-only group (p<0.05). Treatment-related adverse events with CCH

  25. Slide 25: "New" Auxilium: Near Term Priorities

    “New” Auxilium: Near Term Priorities Efficiently integrate Actient Maximize value of current portfolio Stabilize/grow Testim market share & increase unit sales Drive to standard of care in Dupuytren’s for XIAFLEX Grow TESTOPEL, Edex, Osbon ErecAid and Striant use with Urologists Prepare for and succ

  26. Slide 26: Appendix

    Appendix

  27. Slide 27: Non-GAAP financial measures

    This presentation contains pro-forma financial measures that are not consistent with the financial measures that would be reported in financial statements prepared in accordance with generally accepted accounting principles, or GAAP. These non-GAAP financial measures should not be relied upon as an

  28. Slide 28: Reconciliation of GAAP to Non-GAAP Net Income (Loss)

    Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) 3 Months Ended March 31, 2013 3 Months Ended March 31, 2012 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues 66.2 $ - $ 66.2 $ 73.6 $ - $ 73.6 $ Operating expenses: Cost of goods sold 15.1 (0.0) (a) 15.1 16.6 (0.0) (a) 16.

  29. Slide 29: Reconciliation of GAAP to Non-GAAP Net Income (Loss) Footnotes

    Auxilium Reconciliation of GAAP to Non-GAAP Net Income (Loss) 3 Months Ended 3 Months Ended March 31, 2013 March 31, 2012 (a) Costs of goods sold: Employee stock-based compensation (1) (0.0) (0.0) (b) Research and development expenses: Employee stock-based compensation (1) (0.7) (0.6) (c) Selling, g

  30. Slide 30: 1st Quarter 2013 Net Revenue Details

    Auxilium 1st Quarter 2013 Net Revenue Details Increase 2013 2012 (Decrease) Testim revenues- Net U.S. product sales $45.3 $57.9 -22% International revenues 0.2 0.8 -78% Total Testim revenues $45.5 $58.7 -23% XIAFLEX revenues- Net U.S. product sales $12.0 $12.6 -5% International revenues 8.8 2.3 276%

  31. Slide 31: Actient financial information cautionary notes

    The audited financial information and other financial information of Actient contained in this presentation has not been audited or independently verified by Auxilium or its registered independent public accountants. The financial information of Actient is being provided by Auxilium for information

  32. Slide 32: Actient Audited Revenues 2010 - 2012

    Actient Audited Revenues – 2010 - 2012 $ Millions +250% Source: Actient audited financial statements and supporting ledgers. See slide 31 in the Appendix to this presentation for a detailed explanation of, and cautionary statements regarding, the source of the Actient historical financial data. 1 20

  33. Slide 33: Pro Forma As Adjusted 2012 EBITDA

    Pro Forma As Adjusted 2012 EBITDA 1 See slide 34 for details 2 See slides 41-42 for details 3 Reflects full year run rate synergies expected to be achieved by 2015. The majority of run rate synergies are expected to be achieved in 2014. (3) (2) (1)

  34. Slide 34: 2012 Combined Pro Forma As Adjusted Revenues

    2012 Combined Pro Forma As Adjusted Revenues 34 b c a d See slide 31 in the Appendix to this presentation for a detailed explanation of, and cautionary statements regarding, the source of the Actient historical financial data. Auxilium Reported 2012 Revenue 395.3 Less Pfizer Termination Revenue Incl

  35. Slide 35: 2012 Combined Pro Forma Revenues (cont.)

    2012 Combined Pro Forma Revenues (cont.) 35 (d) In 2012, Actient adjusted the return reserve for UCB products to reflect a lower return rate based on actual returns experienced. This reduction in the reserve resulted in higher net revenues recorded. Auxilium believes that $1.5 MM of this reduction i

  36. Slide 36: Auxilium Historical and Pro Forma Financial Performance

    Auxilium Historical and Pro Forma Financial Performance $MM $MM $MM $MM 2010 2011 2012 2010 2011 2012 Revenue PF Adj. EBITDA Gross Profit PF Adj. EBITDA less Capex Note: See slides 37-39 in the Appendix to this presentation for explanation of all adjustments made to audited financial statements of A

  37. Slide 37: Auxilium 2012 Pro Forma Financial Data

    Auxilium 2012 Pro Forma Financial Data EBITDA EBITDA $ millions Revenue Gross Profit Net Income Adjustments EBITDA CapEx Less CapEx As Reported 395.3 $ 316.9 $ 85.9 $ 8.7 $ 94.6 $ 94.6 $ (a) Eliminate Pfizer Termination (92.0) $ (83.7) $ (83.7) $ (83.7) $ (83.7) $ (b) Eliminate Stock Based Compensat

  38. Slide 38: Auxilium 2011 Financial Data

    Auxilium 2011 Financial Data 38 EBITDA EBITDA $ millions Revenue Gross Profit Net (Loss) Adjustments EBITDA CapEx Less CapEx As Reported 264.3 $ 208.7 $ (32.9) $ 7.7 $ (25.2) $ (25.2) $ (a) Eliminate Stock Based Compensation 17.3 $ 17.3 $ 17.3 $ (b) Capital Expenditures - $ - $ (6.6) $ (6.6) $ (c) A

  39. Slide 39: Auxilium 2010 Financial Data

    Auxilium 2010 Financial Data 39 EBITDA EBITDA $ millions Revenue Gross Profit Net (Loss) Adjustments EBITDA CapEx Less CapEx As Reported 211.4 $ 161.7 $ (51.2) $ 6.2 $ (45.0) $ (45.0) $ (a) Eliminate Stock Based Compensation 18.0 $ 18.0 $ 18.0 $ (b) Capital Expenditures - $ - $ (11.3) $ (11.3) $ (c)

  40. Slide 40: Actient 2012 Pro Forma Financial Data

    Actient 2012 Pro Forma Financial Data 41 EBITDA EBITDA $ millions Revenue Gross Profit Net Income Adjustments EBITDA CapEx Less CapEx Per Financial Statements 114.9 $ 85.0 $ (24.2) $ 42.7 $ 18.5 $ 18.5 $ (a) Change in Fair Value of Contingent Consideration - $ 20.3 $ 20.3 $ 20.3 $ (b) TESTOPEL Out o

  41. Slide 41: Actient 2012 Pro Forma Financial Data – Cont'd

    Actient 2012 Pro Forma Financial Data – Cont’d 42 (g) Adjustment represents capital expenditures per statement of cash flows. (f) Respesents a number of smaller adjustments to Revenues and EBITDA that the Company believes are reasonable to include as a pro forma adjustment and provides investors wit

  42. Slide 42: Actient 2011 Financial Data

    Actient 2011 Financial Data 43 EBITDA EBITDA $ millions Revenue Gross Profit Net Income Adjustments EBITDA CapEx Less CapEx Per Financial Statements 58.6 44.3 1.3 $ 14.7 $ 16.0 $ 16.0 $ (a) Change in Fair Value of Contingent Consideration 2.5 $ 2.5 $ 2.5 $ (b) Intangible Asset Impairment 3.2 $ 3.2 $

  43. Slide 43: Actient 2010 Financial Data

    Actient 2010 Financial Data 44 EBITDA EBITDA $ millions Revenue Gross Profit Net (Loss) Adjustments EBITDA CapEx Less CapEx Per Financial Statements 16.7 12.4 (2.8) $ 6.2 $ 3.4 $ 3.4 $ (a) Capital Expenditures - $ - $ (0.1) $ (0.1) $ (b) Adjusted, pro forma non-GAAP 16.7 $ 12.4 $ (2.8) $ 6.2 $ 3.4 $

  44. Slide 44: Actient's Other Products

    Actient’s Other Products Product Therapeutic Area Description (theophylline anhydrous) Respiratory Theophylline is a methylxanthine drug that treats both COPD and asthma Approved in 1983; BC rated generic and not substitutable without physician consent Theo-24 has a narrow therapeutic window with a

Auxilium Pharmaceuticals — UBS Conference (May 2013) on 6ix